News About: Pharm. Industry
Dong-A Pharm nine-month sales rises 13%
Dong-A Pharm, Korea's leading drug maker, said it posted sales of 412.3 billion won for the nine months of this year, up 13.19 percent compared with 364.2 billion won a year ago, due to continued robust sales of presc...
Bayer Korera taking over OTC drugs from Roche Korea.
Bayer Korea may take far aggressive promotional activities on their non-prescription drugs in the market to make their business capacity one step upward next year.
Bayer Korea announced in the middle of this year t...
KPMA redefines scope of entertainment, etc. in fair trade code
The Korea Pharmaceutical Manufacturers Association said it has streamlined its fair trade code in terms of entertainment, amount of pilot batches, donation of research fund, etc. The salient points are:
- The scope...
Domestic pharmaceutical firms to focus on intensive marketing of new drugs in 2005
Following a gloomy 2005 forecast of a local private think tank that Korean economy may fail to emerge from the current economic slowdown and fall into a long-term structural economic slump, a number of domestic pharma...
Bacchus-S to determine as a quasi-drug category next week.
The KFDA mulls over as to whether Bacchus S, a symbolic brand of tonic drink in Korea, should be approved as a quasi-drug, taking quite a long time by deferring its final conclusion. However, it seems to be finalized ...
Vcaps vegetable capsules lands in Korea
Inotech system said it has imported and distributed in Korea the U.S.-based Capsugel's Vcaps vegetable capsules, which are an preservative-free dosage form that retains all the advantages of standard two-piece capsule...
Herbal cold drinks to ignite its hot competition.
The sales of the Ssang Wha tang cold remedy, a drink type of herbal formula, rose up these days by ever increased reordering from the markets along with a chance for the PPA cold remedies to be replaced amid sharply i...
Otsuka Korea begins SWAT study
Otsuka Korea said that since the end of October, it has began conducting its local SWAT (SWitching of Abilify Trial) study to evaluate the safety and efficacy of Abilify, including its tolerability, which was launched...
Handok Pharm, drug wholesalers in love-hate relations
With growing interest over the three-day meetings to be held from November 10 between Handok Pharm and its associate wholesalers, there is general industry consensus that the former needs to come up with best alternat...
Post-tamoxifen use of Femara available in Korea
Novartis Korea said on November 4 that the Korea Food and Drug Administration has approved an extended adjuvant treatment with Femara (letrozole) in postmenopausal women with early breast cancer who had completed five...
